The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer's disease

Alzheimers Res Ther. 2020 Jul 16;12(1):86. doi: 10.1186/s13195-020-00652-z.

Abstract

Background: The neuroprotective role of interleukin (IL)-33 is supported by numerous preclinical studies, but it remains uninvestigated in clinical studies of Alzheimer's disease (AD). We aimed to examine the association between human blood levels of IL-33 and cognitive preservation in amnestic mild cognitive impairment (aMCI) and AD.

Methods: A total of 100 participants (26 controls, 35 aMCI patients, and 39 AD patients) completed two Mini-Mental State Examinations (MMSEs) over a 1-year interval. In all 100 participants at the second MMSE, we examined the plasma levels of IL-33, IL-β, IL-1 receptor agonist (IL-1RA), beta amyloid (Aβ), and tau and apolipoprotein E (ApoE) genotyping; we also performed Hopkins Verbal Learning Test, Trail Making Test, forward and backward digit span, and Clinical Dementia Rating.

Results: IL-33 expression showed a positive trend among controls (1/26 = 3.8%), aMCI (9/35 = 25.7%), and AD (17/39 = 43.6%) (trend analysis: P < 0.001). Patients expressing IL-33 preserved their cognitive function compared with IL-33 non-expressing patients (1-year ΔMMSE, 0.16 ± 1.6 vs - 1.5 ± 2.6; P = 0.006). The cognitive preservation was not associated with the lower levels of Aβ, tau, and ApoE ε4, while higher levels of ApoE ε4 and phosphorylated tau were indeed associated with cognitive decline. The aMCI patients with AD conversion during study period had higher proportion of IL-33(-) than non-AD converters (90.9% vs 53.3%, P = 0.04).

Conclusions: IL-33 or its associated signaling pathways may represent a new treatment paradigm for aMCI and AD.

Keywords: Alzheimer’s disease; Cognitive decline; Cytokine; Interleukin-33; Mild cognitive disorder.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / genetics
  • Amyloid beta-Peptides
  • Apolipoprotein E4
  • Biomarkers
  • Cognitive Dysfunction* / genetics
  • Humans
  • Interleukin-33

Substances

  • Amyloid beta-Peptides
  • Apolipoprotein E4
  • Biomarkers
  • IL33 protein, human
  • Interleukin-33